{
  "id": 6867672,
  "title": "SK Biophama Presses Ahead with Opakalim License Deal Despite FDA Hold",
  "url": "https://urgent.news/2026/09/11/sk-biophama-presses-ahead-with-opakalim-license-deal-despite-fda-hold",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-11T11:57:34.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=276739"
  },
  "original_language": "en",
  "account": null,
  "summary": "SK Biopharmaceuticals, which is pursuing a licensing deal worth up to 1.1 trillion won ($816.75 million) for an epilepsy drug candidate, has encountered an unexpected hurdle after the U.S. Food and Drug Administration (FDA) placed the candidate under a partial clinical hold. The company, however, pl",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}